Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4dcc7d7259def30e33dbf2ba33a42672 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-50 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-5434 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-54 |
filingDate |
2016-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_109cef1bdeb78e566db3d4170cadbb33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_052a0bebdf408d3070511ee9bd655e70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ba73496ca3a9bd2c931a435d4ba2e80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f055267a1c1e2ee57e93273e5687ae3f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fde414afabede9b61286ba0e48980388 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_875f6e0e41d0786f9c3138b2ce4d7cdf |
publicationDate |
2017-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2017062953-A1 |
titleOfInvention |
Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
abstract |
The present invention relates to modified forms of IL-12. These modified forms of IL-12 may be engineered to have a shortened in vivo half-life compared and/or enhanced localization of biological effects compared to that of corresponding non-modified form of IL-12. Short half- life and membrane bound forms of IL-12 may provide greater therapeutic control for in vivo therapeutic delivery, in particular when used in combination with ligand inducible delivery of IL-12. Modified forms of IL-12 engineered to have shortened in vivo half-life and/or enhanced localization of biological effects include heterodimeric p35/p40, single chain and membrane bound forms of IL-12 wherein a naturally occurring IL-12 amino acid sequence is genetically modified to destabilize IL-12 tertiary structure/polypeptide folding and enhance susceptibility of the IL-12 molecule to in vivo proteolytic degradation. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020252404-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020123716-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020255014-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023004282-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11058725-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11655277-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021232200-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018132494-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11358999-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018209194-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018195410-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11118168-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019241315-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11421010-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11608362-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3523323-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021040736-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020160350-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020061184-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10308913-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10251922-B2 |
priorityDate |
2015-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |